Skip to main content

The context you need, when you need it

When news breaks, you need to understand what actually matters — and what to do about it. At Vox, our mission to help you make sense of the world has never been more vital. But we can’t do it on our own.

We rely on readers like you to fund our journalism. Will you support our work and become a Vox Member today?

Join now

Now you can use all that startup stock to get a bank to loan you money

It’s hard to be rich if your riches aren’t real yet.

Dow Jones Industrials Average Closes Above 26,000 For First Time
Dow Jones Industrials Average Closes Above 26,000 For First Time
Photo by Spencer Platt/Getty Images,

If you’re an executive or employee at a valuable startup, you could be sitting on millions of theoretical dollars but have trouble with the very untheoretical tasks of paying off a college education or buying a fancy home.

Ask a bank for a personal loan? Not so easy when your net worth is in the form of shares of a private company that a bank can’t easily value.

Now, though, the secondary market SharesPost is creating a program that will route cash from 10 big banks to startup workers, who will use their company equity as collateral for the loan. SharesPost traditionally allows shareholders to sell their stock options on the portal — but that means they could also be losing money if their company keeps rising in value.

A loan allows them to keep the cash and the equity.

“It makes the options more valuable to employees because they’re not going to be locked up before an IPO for 10 years,” said SharesPost CEO Greg Brogger. “Now they’re going to be able to buy a house, buy a car, get a college education.”

The cost though for this type of loan would be steep and could be as high as 12.5 percent: The banks will still levy about a 5 percent fee upfront for each loan, SharesPost said, and then there’s an accruing interest rate of about 3 percentage points more than the so-called prime rate, which is about 4.5 percent as of this week.

SharesPost will serve as a broker, helping the bank determine how much the borrower’s stock is worth and then actually administering the loan.

In the past, banks or individual lenders might have allowed someone to use their startup equity as collateral in special cases — maybe the borrower is a particularly large client, Brogger said. And if people already have other assets — a home, a car or public company stocks — then they can offer those to a bank as collateral.

But as companies stay private for longer and longer, more and more workers at startups are left needing cash sooner.


This article originally appeared on Recode.net.

More in Technology

Podcasts
Are humanoid robots all hype?Are humanoid robots all hype?
Podcast
Podcasts

AI is making them better — but they’re not going to be doing your chores anytime soon.

By Avishay Artsy and Sean Rameswaram
Future Perfect
The old tech that could help stop the next airborne pandemicThe old tech that could help stop the next airborne pandemic
Future Perfect

Glycol vapors, explained.

By Shayna Korol
Future Perfect
Elon Musk could lose his case against OpenAI — and still get what he wantsElon Musk could lose his case against OpenAI — and still get what he wants
Future Perfect

It’s not about who wins. It’s about the dirty laundry you air along the way.

By Sara Herschander
Life
Why banning kids from AI isn’t the answerWhy banning kids from AI isn’t the answer
Life

What kids really need in the age of artificial intelligence.

By Anna North
Culture
Anthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque messAnthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque mess
Culture

“Your AI monster ate all our work. Now you’re trying to pay us off with this piece of garbage that doesn’t work.”

By Constance Grady
Future Perfect
Some deaf children are hearing again because of a new gene therapySome deaf children are hearing again because of a new gene therapy
Future Perfect

A medical field that almost died is quietly fixing one disease at a time.

By Bryan Walsh